Diabetalong, nā Lūkiniʻāina Lūkini o nā lāʻau lapaʻau me nā kumukūʻai a me nā loiloi

ʻO ka Diabetalong kahi lāʻau lapaʻau pūnaehana e hoʻohana ʻia ma ke ʻano he ʻāpana o ka monotherapy a i ʻole nā hoʻoponopono hoʻoponopono lāʻau hou no ka maʻi maʻi ʻo ka maʻi 2. Ua kuhikuhi ʻia nā papa Diabetalong ma ka lilo ʻole o ka hopena koʻikoʻi o ka hoʻoponopono ʻana i ka meaʻai a me ka hana kūlohelohe o ka mea maʻi, ka mea e like me kona wā a me kāna mau ʻano.

Pono e hoʻohui pū me ka lāʻau lapaʻau me ka lāʻau lapaʻau (papaʻaina 9) - pono kēia e pale ai i ka hoʻoulu ʻana a hypoglycemic a hoʻonui i ka hana o ka ʻoihana.

ʻO kahi hiʻohiʻona kūikawā o ka lāʻau lapaʻau ka hoʻokuʻu mau loa o ka mea ikaika, hiki iā ia ke hōʻemi i kēlā me kēia lā i ka lā lapaʻau a no ka hōʻoia i ka hoʻemi ʻana o ka glucose i loko o kahi mehana o ke koko kahe.

Ke noi

ʻO "Diabetalong" e pili ana i ka hui o nā lāʻau lapaʻau me ka hopena hypoglycemic, ka mea i hoʻohana ʻia no ka mālama nui ʻana no ka non-insulin-Mellitus e pili ana i ka maʻi. ʻO ka mea hana ikaika o nā papa he gliclazide.

ʻO kēia lāʻau lapaʻau me ka hana koho kiʻekiʻe, me ka bioavailability a hoʻonui i ka pale ʻana i nā ʻano kai kūlohelohe.

ʻO ka hopena therapeutic o ka lāʻau lapaʻau ma muli o nā waiwai o gliclazide, i waena o ia:

hoonui i ka huna o ko lakou iho i ka insulin, kahi e ho'ēmi ai i ka nui o nā hormone i hoʻopaʻa ʻia i loko o ke koko,
ka hooulu ana o ka hana o nā polela beta (nā selela e hana i ka ʻāpana pancreatic a hoʻopaʻa i kona waiwai endocrine),
Ka hoʻōho maʻamau o nā hana kāohi (ʻoi aku paha i nā mea maʻi me ka momona o ke ʻano maʻi diabetes, 2 a me 4 mau kiʻekiʻe).
ka pale ʻana o ka platelet agregation (fusion) a me ka pale ʻana o ka thrombocytopenia, thromboembolism a me thrombosis.

Ua hōʻike ʻia ua hana ʻo Diabetalong i ka hana antisclerotic a ua hōʻemi nui ia i ka hiki ke hoʻomohokū i nā hoʻopiʻi kūlohelohe mai ka puʻuwai, nā kīʻaha koko, nā ʻāpana a me ka lolo.

ʻO ka mana ikaika o ka lāʻau lapaʻau ke hoʻokuʻu i kahi lōʻihi, a hiki ke hoʻonui i kona kiʻekiʻe nui i loko o nā hola 4-6.

Mālama ʻia ka hopena o ka lāʻau a hiki i nā hola 10-12, a ʻo ka hapalua-ola mai 6 a 12 mau hola (ma muli o ka hana o ka ʻōnaehana renal).

Ke hōʻike nei i ka lāʻau lapaʻau ʻo ka type 2 ka mellitus diabetes type - he ʻano kūʻokoʻa kūmole i ka maʻi e hoʻomōhala ʻia ai e ka mea maʻi maʻi (hyper stabilly glucose i loko o ke koko) a me ka ʻike ʻole ʻana i ke kūlohelohe i ka insulin.

E hoʻokuʻu i ke ʻano

Loaʻa i ka "Diabetalong" i hoʻokahi palapala hoʻohālikelike - hoʻonui ʻia ʻana i hoʻokuʻu ʻia a hoʻokuu paha i hoʻokuʻu ʻia. Kihua i kahi mea lapaʻau huahana hana i ʻelua mau pona o ka lāʻau lapaʻau.

30 mg (pūpū o 30 mau ʻāpana) - pono ʻia no ka hoʻomaka mua ʻana o ka mālama ʻana,
60 mg (pūpū o 60 mau ʻāpana).

Hoʻohana ka mea hana i nā hoʻohui hoʻohui pono e like me nā mea kōkua, no ka laʻana, ka calcium stearate, silicon dioxide a me talc.

Hiki i ke kūleʻa ʻana i ka lāʻau lapaʻau ke hiki i ka lactose (ma ke ʻano o kahi monoholatoma) - nā molekō o ke kō waiū waiū me nā molekele wai paʻa.

ʻO ka poʻe maʻi me ka congenital i loaʻa ʻole ka maʻi lactase e loaʻa i nā pilikia dyspeptic, no laila, me kēia pathology, analogues a me nā mea e loaʻa ai i nā waiwai like ʻole i loaʻa i ka huka waiū e pono ke koho ʻia.

Ke keʻokeʻo a papa ʻa nā papa papa ma ke ʻano o kahi cylinder.

I kekahi mau hihia, hiki i ka lāʻau lapaʻau ke kiʻi ponoʻaneʻane - ua hōʻike ʻia kēia ʻano e ka kahele ʻole ʻana o ka waihona talcum a ʻaʻole i hoʻopā i ka nā maʻi pharmacological o ka lāʻau.

Nā ʻōkuhi no ka hoʻohana

Nānā nā ʻōlelo no ka hoʻohana ʻana i "Diabetalong" lawe i ka lāʻau lapaʻau 1 i 2 mau manawa i ka lā (e pili ana i ka ʻano lāʻau).

Inā he mau papa ʻaina i kēlā me kēia lā i ka papa ʻaina lā 1-2, pono lākou e lawe ma ka manawa o ke kakahiaka.

ʻOiai ke kūpono o ka annotation e lawe i nā papa ma waena o ka papaʻaina, ʻoi aku ka maikaʻi o ka mālama ʻana inā e lawe ʻoe i ka "Diabetalong" 10-20 mau minuke ma mua o ka ʻai ʻana.

Inā poina ka mea maʻi e lawe i ka pōpoki, pono ia e hoʻomau i ka mālama ʻana mai ka noi hou e hāʻawi ʻia ana e ka hoʻoponopono regimen o ka hoʻohana a me ka maʻi maʻi.

Mai hoʻonui i ka wai (no ka laʻana, ʻaʻole hiki iā ʻoe ke lawe i nā kīpī i hala i ke ahiahi), no ka mea hiki i kēia ke alakaʻi i kahi hōʻeha ʻana o ka hypoglycemia a me ka hoʻomohala ʻana o kahi coma, inā no nā poʻe ma luna o 65 a me nā poʻe maʻi i ka hopena.

Nā Hoʻohui

Ma mua o ka lawe ʻana i kekahi lāʻau lapaʻau hypoglycemic pono, pono e kamaʻilio aku i ke kauka, a i ke kūkaʻi ʻana o ka mālama ʻana, pono ia e kāohi i ke kiʻekiʻe o ke kō a me ka hana o ke koʻi.

Hāʻawi ʻia ka lawe ʻia ʻana i nā lāʻau lapaʻau i kēia pūʻulu no ka maʻi ʻano 1, no ka mea hiki i kēia ke alakaʻi i ka nui o ka hōʻemi o ka insulin i nā kiko.

Hoʻokomo ʻia nā huahana i hoʻokumu ʻia ʻo Glyclazide i nā wahine hāpai a me nā māmā hānai, no ka mea hiki iā lākou ke hōʻeha i nā pathologies endocrine nui a me nā abnormalities cardiac ma ka pūpū a me ka pēpē.

ʻO nā contraindications ʻē aʻe no ke kuhikuhi ʻana i ka maʻi Diabetalong e loaʻa:

nā maʻi ākea o ka pūpū a me ka ate, e alakaʻi ana i ka hoʻopiha piha aiʻole i ka ʻāpana paha,
nā huakino e hele nei me ka wā o ka hōʻole hewa o ka metabolism,
mau hopena hoʻonā o ka intolerance a i ʻole hypersensitivity i nā mea kūloko mai ka hui o derivatives sulfonylurea a sulfonamides paha,
maʻi koma maʻi a me kona mau kūlana,
ka nele o nā enzymes e wāwahi i ka waiu waiu (ma muli o ka hāʻule o ka lactose i ka hoʻohui).

ʻO ka maʻi diabetes kā ʻia wale nō no ka mālama ʻana i nā maʻi maʻi makua.

No ka poʻe i ʻoi aku ma mua o 65 mau makahiki, hiki ke kuhikuhi ʻia ka lāʻau lapaʻau ma lalo wale nō o ka nānā ʻana i nā pā kuʻuna biochemical o ke koko a me ka waiʻai, a me ka clearance creatinine. I ke koho ʻana, pono e noʻonoʻo pono ʻia ka nui o nā lāʻau lapaʻau. Ua pāpā ʻia ʻo ia e lawe i ka gliclazide me nā lāʻau systemic antifungal e pili ana i ka miconazole, a me Danazol a me Phenylbutazone.

Pono e hoʻomaka i ka mālama ʻana me kahi hōʻemi haʻahaʻa loa o 30 mg (tablet hoʻokuʻu ʻia i hoʻololi ʻia). Ma ka dosage like, pono ʻia e mālama ʻia nā kānaka e hōʻemi i ka hoʻomohala ʻana o nā kūlana hypoglycemic. Aia nā mea pilikia i ka:

pono ʻole ke kīwī me ka lawa o nā minamina a me nā waiū a me ka nui o ka meaʻai i nui i nā pōkoli māmā a me nā puna,
elemakule (ma luna o 65)
ka haʻalele ʻana i ka moʻolelo o nā maʻi o ka mālama ʻana me ka hoʻohana ʻana i nā lāʻau lapaʻau e hōʻemi i ka glucose koko,
nā hana hoʻonāukiuki i ka hana o nā kūloko adrenal a me ka kelepona pituitary,
ʻaʻole lawa i ka hana ʻana o ka nui o nā hormone thyroid o ka nui o ka thyroid gland,
hupaia arteriosclerosis,
nā maʻi puʻuwai koʻikoʻi (me nā maʻi naʻau coronary 3 a me 4 degere).

ʻO ka lāʻau lapaʻau i loko o kahi iniha o 30 mg mau ʻia i hoʻokahi lā i ke kakahiaka ma mua o i ke kakahiaka ʻaina kakahiaka.

No nā kumuwaiwai ʻē aʻe o ka maʻi, ua helu ʻia ka pākiha i ke ʻano o ka palalīwī o ka patology, ka makahiki o ka mea maʻi, ka hoʻokaʻa o ke koko a me nā mea ʻē aʻe o ka hoʻāʻo ʻana o ka taiwa a me ka koko.

ʻAʻole pono nā lā o kēlā me kēia lā e 120 mg (2 mau papa o 60 mg a i ʻole 4 mau papa o 30 mg).

Nā hopena hopena

ʻO nā hiʻohiʻona hiʻona e pili pū ana me Diabetalong he mau ʻeha, hōʻeha i ka ʻono, anemia hemolytic, a me nā hopena alia i loko o ke ʻano o ka ʻeha ʻula. ʻO ka maʻamau, loaʻa nā lono o nā pilikia ʻē aʻe, kahi e.

āhāhuʻe
hoʻomāʻeha ʻokoʻa
e haʻalulu ana i ke kino
ʻike hopuna hoʻonaninani,
paʻakikī ka hanu a me ka hana ʻana,
ka ʻōmaʻomaʻo o ka ʻili a me nā membusous o ka sclera o ka maka (hepatitis o ke ʻano cholestatic),
ka hoemi ana ike aniani,
hoʻonui i ke koko.

Ma kekahi mau hihia, ʻo ka lawe ʻana i ka lāʻau "Diabetalong" hiki ke hoʻonāukiuki i ka hōʻeha ʻino i loko o ka ate, me ka hoʻoweliweli ʻana i ke ola o ka mea maʻi. Hiki i ka lāʻau lapaʻau ke hoʻopilikia maikaʻi i ka hana o ka hematopoiesis o ka ʻōpū o ka iwi, no laila, e hana ʻia ma lalo o ka mākaʻikaʻi koʻikoʻi o kahi loea, i hui pū ʻia me kahi therapeutic diet me ka hoʻoikaika kino o ke kino.

Ua manaʻo ʻia ke kumukūʻai o "Diabetalong" kūpono no nā māhele āpau o ka maʻi, ʻo ka mea lapaʻau i ke kumukūʻai e pili ana i ka māhele haʻahaʻa haʻahaʻa. ʻO ka kumukūʻai awelika no kahi pā o 60 papa he 120 rubles.

Analogues o ka lāʻau e pono ai no ka hihia o kahi hopena al a i ʻole mololopole i kekahi o nā mea o ka lāʻau. E kaohi i ke kiʻekiʻe o ke kō, hiki i ke kauka ke kuhikuhi i nā kālā mai ka hui o nā derivatives o sulfonylurea a i nā lāʻau lapaʻau hypoglycemic like me ka hopena therapeutic like.

"Diabeton" (290-320 rubles). Hoʻolālā analogue o "Diabetalong" me ka waiwai like. Hoʻomaopopo ka lāʻau lapaʻau e ʻoi aku ka maikaʻi ma muli o ka hoʻomaka wikiwiki o ka hopena therapeutic - loaʻa ke kūlohelohe loa o ka gliclazide i loko o ke koko koko i loko o nā hola 2-5.
"Gliclazide" (100-120 mau rubles). ʻO kahi hoʻomākaukau e hypoglycemic i ke ʻano o kahi paura, kahi hōʻailona hoʻohui o Diabetalong.
"Kūkākūkā lōʻihi" (170-210 rubles). ʻO ka lāʻau lapaʻau lōʻihi, aia i ka metformin. Hiki ke hoʻohana ʻia e like me ka lāʻau nui a hui pū ʻia me ka insulin a me nā lāʻau ʻē aʻe e hōʻemi i ke kō.

ʻAʻole hiki ke hoʻopau i nā lāʻau me nā hypoglycemic waiwai ma luna o lākou iho, no ka mea e koi iki lākou i ka hoʻihoʻi ʻana me ka hoʻoneʻaweʻana i ka dosie like ʻole a me ka mālama pinepine ʻana i nā lolo a me nā urine biochemical. Hiki ke koho ʻia nā lāʻau lapaʻau e like me kēia loea i kahi loea.

Ke keu

Inā ʻaʻole ʻoe i oi aku i ka hopena i ʻōlelo ʻia a me ka hoʻomaka ʻana o nā hōʻailona o ka hōʻemi hypoglycemic hōʻeuʻeu, pono ʻoe e hoʻomaʻamaʻa i kahi hopena glucose (40% - 40-80 ml), a laila hoʻoili i kahi ʻōmole 5-10% me kahi infusate. Me nā hōʻailona maʻalahi, hiki koke iā ʻoe ke hoʻonui i ke kiʻekiʻe o ke kō me nā huahana e loaʻa ana i nā sucrose a i ʻole nā mea momona māmā.

ʻO nā loiloi e pili ana i ka lāʻau lapaʻau no ka maʻi "Diabetalong" he mea kūpono loa.

ʻO kahi mea hoʻohana ʻo Venera87 mai ke kūlanakauhale o Kursk i kahi loiloi http://otzovik.com/review_3106314.html e ʻōlelo ana ua kōkua ke hāmeʻa i kona mau mākua makua e ʻona i kā lākou mau kūpaʻa. Ua kau ʻia ka lāʻau lapaʻau i loko o kahi waihona o 30 mg hoʻokahi i ka lā a ua hopu ikaika ʻia e ke kauka. ʻAʻole i loaʻa nā hopena kūpono i ka wā mālama.

Ua ʻōlelo pū kekahi ʻo Vitaly Koval i ka lāʻau lapaʻau a ʻōlelo aku ʻo ia i kōkua i nā papa papa i kona kupuna wahine i ka hoʻomau ʻana i nā kola o nā kō (https://health.mail.ru/drug/diabetalong/).

Akā ʻo Ivan, ma ke kuhi ʻana, ʻaʻole i kūpono ka lāʻau lapaʻau i kona makuakāne, a ma muli o ke ʻano o ka mālama ʻana, hoʻomaka ka mea hoʻomanawanui i ka hōʻeha nui ʻana ma ka ʻōpū o ka ʻōpū, no ka mea ʻo ia ke keʻoki ʻia ai ka mālama ʻana i 10 mau lā ma hope o ka hoʻomaka ʻana o ka lawe ʻana i nā papa (http: //www.imho24 .ru / kuhikuhi / 57004 / # review77231).

"Diabetalong" - kahi lāʻau lapaʻau e pono ke kuhikuhi wale ia e ke kauka me ka helu pākahi ʻana o ka maʻi a me ka regimen. Inā ʻaʻole pono ka lāʻau lapaʻau i kahi mea maʻi maʻi kūikawā, pono ʻoe e nīnau i ke kauka a koho i kahi lāʻau lapaʻau hypoglycemic kūpono.

Mālama a hoʻohele paha:

Diabetalong ma Moscow

ʻO ka lāʻau lapaʻau hypoglycemic Oral, kahi derony o ka sulfonylurea o ka lua o ka hanauna.

Hoʻonui ia i ka mea huna o ka insulin i ka pancreas, hoʻohaʻahaʻa i ka pae o kaʻae i loko o ke koko, hoʻonui i ka hopena o ka insulin-secretory o ka glucose a hoʻonui i ka paʻakikī o nā ʻiʻo peripheral i ka insulin. Ma hope o 2 mau makahiki o ka mālama ʻana, ʻaʻole nui ka poʻe maʻi e hoʻomohala i ka hoʻohui i ka lāʻau lapaʻau (ʻoi aku ka piʻi o ka nui o ka insulin postprandial a me ka hilo ʻana o C-peptides e hoʻomau).

Hoʻololi i ka manawa manawa mai ka manawa o ka ʻai ʻana a i ka hoʻomaka ʻana i ka huna ʻana i ka insulin.

Hoʻihoʻi hou i ka makamua o ka loaʻa ʻana o ka inikua o ka insulin i ka pane ʻana i ka intake glucose (like ʻole me nā derivatives sulfonylurea ʻē aʻe, he hopena nui ia ma ka lua o ke ʻano o ka honi ʻana).

Hoʻonui ʻia ia i ka lua o ka neʻe o ka hana huna o ka insulin. Hoʻemi i ka punaha o ka hyperglycemia ma hope o ka ʻai ʻana (a hoʻemi i ka hyperglycemia postprandial).

Hoʻonui ʻo Glyclazide i ka mahele o ke kino peripheral i insulin (i.e., he hopena i hoʻihoʻi ʻia i ka extrapancreatic). I ka kiko o ka ʻiʻo, ka hopena o ka insulin i ka uptake glucose, ma muli o ka hoʻomaikaʻi ʻana o ke ʻano maʻi i ka insulin, i hoʻonui nui ʻia (a i + 35%), ʻoiai ka mea e hoʻoulu ai ka glycazide i ka hana o ka glycogen synthetase.

Hoʻēmi i ka hana o ka glucose i loko o ka ate, ka hoʻomaʻamaʻa ʻana i nā kūlā glucose wikiwiki.

Hoʻopili i nā mea pili i ka metabolism, hiki ke hoʻonui ka gliclazide i ka microcirculation.

Ke hōʻemi nei ka lāʻau lapaʻau i ka hopena o ka thrombosis liʻiliʻi, ke hoʻoikaika i nā hana ʻelua e komo ai i ka hoʻomohala ʻana o ka hoʻopiʻi i ka maʻi mellitus. hana viva endothelial a me ka hana he nui o ka kiko o ka plasminogen kiko hana.

Loaʻa i ka Glyclazide nā mea antioxidant: e hōʻemi ana i ka pae o lipid peroxides i loko o ka plasma, e hoʻonui ai i ka hana o ke kaila o ke koko reddroid dismutase.

Ma muli o nā hiʻohiʻona o ka ʻano dosage, kahi pākahi o kēlā me kēia lā o ka papa Diabetalong® 30 mg e hāʻawi ana i kahi hōʻola kūpono o nā gliclazide i loko o ke koko koko no 24 mau hola.

Ma hope o ka lawelawe waha, ua hoʻopiha piha loa ʻia ka gliclazide mai ka ʻāpana kūwili. ʻAʻohe ʻai i ka ʻai ʻana.

Ke hoʻonui mālie nei ka ʻike ʻana o ka mea hana i ka plasma koko, a hiki i ka nui a hiki i ka pā poli 6-12 mau hola ma hope o ka lawe ʻana i ka lāʻau. He haʻahaʻa loa ka ʻano o ka wae ʻana.

ʻO ka pilina ma waena o ke ʻano a me ka neʻe o ka lāʻau lapaʻau ma ka kaila koko he linear hilinaʻi i ka manawa i ka manawa.

ʻO ka wahī a me ka metabolism

ʻO ka pilina o ka protein plasma e pili ana i ka 95%.

Hoʻonohonohoʻia ia i loko o ka ate a hoʻopili i ka nui o nā keiki. ʻAʻohe huahana metabolites ikaika i loko o ka plasma.

Lawe ʻia ka hana e nā keiki ma ke ʻano o ka metabolites, ʻoi aku ka liʻiliʻi o 1% o ka lāʻau i ka excreted i loli ʻole.

T1 / 2 ma kahi he 16 mau hola (12 i 20 mau hola).

ʻO ka pharmacokinetics i nā hihia lapaʻau kūikawā

I ka poʻeʻelemakule, ʻaʻohe i nānā ʻia nā hoʻololi koʻikoʻi i loko o nā pānaʻi pharmacokinetic.

- Kauka 2 diabetes mellitus i hui pū me ka papa hana o ka meaʻai i ka liʻiliʻi o kaʻai a me ka hoʻomaʻamaʻa.

Pono ʻia ka lāʻau lapaʻau no ka mālama ʻana wale nō. o nā pākeke.

ʻO 30 mg ua hoʻololi ʻia-hoʻokuʻu ʻia ʻO nā papa Diabetalong® e lawe maʻamau ʻia 1 mau manawa / lā i ka wā kakahiaka.

No nā poʻe maʻi i loaʻa ʻole ma mua o ka hoʻomaikaʻi ʻana (me ka poʻe ma luna o 65), ʻo ka hoʻomaka mua ma ka 30 mg. A laila koho ʻia ka pākēnē ke kū hoʻokahi a hiki i ka hopena hopena makemake ʻia.

Pono e hoʻokau ʻia ka maʻi ʻaina e like me ka pae o ka glucose i ke koko ma hope o ka hoʻomaka ʻana o ka mālama ʻana. ʻO kēlā me kēia loli ka hopena i hoʻopaʻa ʻia ma hope o ʻelua mau pule ʻelua.

Hiki i ka palena o kēlā me kēia lā nā loli mai 30 mg (1 tab.) A 90-120 mg (mauʻu 3-4.). ʻAʻole pono nā lā o kēlā me kēia lā e 120 mg (4 papa).

Hiki ke Diabetalong® ke hoʻololi i ka maʻamau gliclazide tablet maʻamau (80 mg) i loko o nā papa o 1 i 4 papa / lā.

Inā poino ʻoe i hoʻokahi mau helu a i ʻole paha ka lāʻau lapaʻau, ʻaʻole hiki iā ʻoe ke lawe i kahi kiʻekiʻe kiʻekiʻe ma kahi aʻe (i ke kakahiaka aʻe).

Ke hoʻololi nei i kekahi lāʻau lapaʻau hypoglycemic hou me nā papa Diabetalong® 30 mg, ʻaʻohe pono o ka manawa transitional. Pono ʻoe e haʻalele i ka ʻai i kēlā me kēia lā i kekahi lāka hou aku a i ka lā aʻe e hoʻomaka i ka lawe ʻana i kēia lāʻau lapaʻau.

Inā loaʻa i ka mea maʻi ka hopena me ka sulfonylureas me ka hapalua hapalua, a laila e nānā pono ana (ka nānā ʻana o ka glucose koko) no nā hebedoma 1-2 pono e pale ai i ka hypoglycemia ma muli o ke ʻano o nā hopena i koe o ka hopena ma mua.

Hiki ke hoʻohana ʻia i ka Diabetalong® e hui pū me ka biguanides, alpha glucosidase inhibitors a i ʻole insulin.

ʻO ka maʻi me ka maʻalahi i ka hoʻololi ʻole i ke aʻa la i ka laau i kauoha ia i loko o like me ka mea no ka mea maʻi me ka hana renal maʻamau. I pilikia kaumaha ʻole Contraindicated ʻo Diabetalong®.

I nā mea maʻi i ka hopena o ka hoʻomohala ʻana i ka hypoglycemia (ʻaʻole i lawa a i ʻole ke kaupaona ʻana, ka hōʻeha a i ʻole ka hoʻopaʻi ʻana i ka hopena o ka endocrine i loko o ka maʻi - hipuitary a me adrenal insufficiency, hypothyroidism, hiki ke hoʻopau ʻia i nā glucocorticosteroids ma hope o ka lōʻihi a / a i ʻole ka hoʻoponopono ʻana i ka nui, nā maʻi koʻikoʻi o ka ʻōnaehana cardiovascular system / maʻi maʻi coronary hōʻeha nui, ʻo ka carotid arteriosclerosis, ākea ākea ka atherosclerosis /) ua kauoha ʻia e hoʻohana i ka palena haʻahaʻa (30 mg 1 manawa / lā) o ka lāʻau Diabetalong®.

ʻO ka Hogoglycemia (i ka hana hewa ʻana o ka hoʻoponopono nui a me ka ʻai ʻole). hōʻeha, ka ʻōpū, ka pōloli, kahe nui ʻana, ka nāwaliwali loa, ka palpitations, arrhythmia, nui ke koko, ka ʻalo ʻana, ka ʻomaʻeha, ka hoʻomāhuʻaka, ka luhi, ka hopohopo, ka huhū, ka pīhoihoi, ka hiki ʻole i ka pīhoihoi a me ka lohi i ke ʻano, ke kaumaha, ka maʻiʻike, ka aphasia , puʻuhū, paresis, ʻeha haunaele, hoʻowalewale, ka manaʻo o ka helplessness, nalowale o ke kāohi ponoʻī, delirium, cramps, papaho pāpuhi, bradycardia, nalowale o ka noʻonoʻo, coma.

Mai ka pūnaehana hana ʻana: ʻōpū, ka luaʻi, ʻeha, ʻeha o ka ʻōpū, constipation (ke ʻano o ke ʻano o kēia mau maʻi i ka wā i lawe ʻia me ka meaʻai), ʻaʻole iki - hana i nā hana ate (hepatitis, hoʻonui i ka transaminases hepatic, ka alkatine phosphatase, jaundice cholestatic - koi i ka hoʻihoʻi ʻana i ka lāʻau).

Mai nā ʻekopa hemopoietic: pale ʻana i ka hematopoiesis sums bone (anemia, thrombocytopenia, leukopenia, granulocytopenia).

Nā maʻi kūwaha: pruritus, urticaria, ʻiliʻili ma ke kino, e komo pū ai maculopapular a bullous), erythema.

Nā ʻili: ʻike maka.

Nā hopena ʻaoʻao maʻamau o ka ʻoniʻoniʻo: erythropenia, agranulocytosis, anemia hemolytic, pancytopenia, vasculitis allergic, pilikia hooweliweli ma ka ola.

Nā Hoʻohui

- momo type diabetes

- ka maʻi ketoacidosis maʻi, diabetes precoma, diabetes coma,

ʻO ka ʻeha a me / a me ka palaualelo ʻole,

- makahiki a hiki i ka 18 makahiki

- ka wā hana umauma (lactation),

- ka loli a lactose congenital, hapa lactase a malabsorption glucose-galactose,

- Hypersensitivity i gliclazide a i ʻole nā mea hoʻonani o ka lāʻau lapaʻau, i nā derivatives sulfonylurea, i sulfonamides.

ʻAʻole koi ʻia e hoʻohana i ka lāʻau i ka wā like me ka hui me phenylbutazone a dana dana.

Me ka ʻaʻole e mālama: ʻōpūʻelemakule, ʻōpiopio a / a ʻole ke pale ʻole ʻana i ka maʻi, nā maʻi hōʻeha o ka ʻōnaehana cardiovascular (me ka maʻi ʻōpū o ka coronary, atherosclerosis), hypothyroidism, adrenal a pituitary insufficiency, hypopituitarism, renal a / a i ʻole kaulike ʻole, terapi lōʻihi me ka corticosteroids, ʻokoholima, lawa ʻole. dehydrogenase glucose-6-phosphate.

ʻŌpū a me ka lactation

ʻAʻoheʻike me kahi gliclazide i ka wā hāpai. ʻAe ʻia ka ʻikepili ma ka hoʻohana ʻana i nā derivatives sulfonylurea i ka wā hapai.

I nā haʻawina ma nā holoholona holoholona, ʻaʻole i ʻike ʻia nā hopena teratogenic o gliclazide.

No ka hōʻemi i ka hopena o ka malenation malenital, pono ka hoʻokele (kūpono pono i ka maʻi maʻi) o ka maʻi mellitus.

ʻAʻole hoʻohana ʻia ka lāʻau hypoglycemic oral i ka wā hāpai. ʻO ka lāʻau lapaʻau i koho no ka mālama ʻana i ka maʻi maʻi i nā wāhine hāpai i ka insulin. Ke paipai ʻia e pani i ka waiwai o ka lāʻau hypoglycemic waha me ka hoʻōla ʻana o ka insulin i ka wā i hāpai ʻia ai kahi hapaha hoʻolālā, a inā inā loaʻa ka hānau ʻana i ka wā e lawe nei i ka lāʻau.

Ke noʻonoʻo nei i ka hapa ʻole o nā ʻike i ka waiwai o ka gliclazide i ka umauma umauma a me ka hopena o ka hoʻouluʻana i ka hypoglycemia neonatal, ka umauma o ka maʻi o ke kūleʻa ʻana i ka wā o ka lāʻau lapaʻau.

Hoʻohana i nā keiki

Contraindicated i nā keiki ma lalo o 18 mau makahiki o ka makahiki.

Nā Hoʻomaka hypoglycemia, ʻike hemahema, hypoglycemic coma.

Lāʻau: inā ʻike ka mea maʻi, e lawe i ke kō i loko.

ʻOi paha ka hoʻomohala ʻana i nā kūlana hypoglycemic koʻikoʻi, ka hele pū ʻana me ka coma, kaʻaila a i ʻole nā ʻano neurological ʻē aʻe. Inā ʻike ʻia kēlā mau hōʻailona, pono ka mālama olakino a me ka haukapila koke ʻia.

Inā kānalua a hopu ʻia paha ka comog hypoglycemic, he 50 ml o ka hopena o 40% dextrose (glucose) i hoʻopaʻa koke ʻia i ka mea maʻi. A laila, ke mālama ʻia kahi hopena o 5% dextrose (glucose) i mea e mālama ai i ka pae o ka glucose i loko o ke koko.

Ma hope o ka ʻike hou ʻana, pono e hāʻawi i ka mea ʻai i ka mea maʻi i ka momona hoʻokaʻawale ʻia (i mea e pale ʻole ai ka hana hou o ka hypoglycemia).

ʻO ka mālama pono ʻana i nā pae hāhā o ke koko a me ka nānā ʻana o ka mea maʻi e lawe ʻia aku ma kahi o 48 mau hola ma hope.

Ma hope o kēia manawa o ka manawa, e pili ana i ke ʻano o ka mea maʻi, ua hoʻoholo ke kauka komo i ka pono no ka nānā hou.

ʻAʻole kūleʻa ʻia ʻo Dialysis ma muli o ka hoʻopio ʻana i ka gliclazide i nā protein plasma.

Hoʻoulu ʻo Glyclazide i ka hopena o nā anticoagulants (warfarin); e koi paha ka hoʻoponopono ʻana o ka anticoagulant.

Hoʻohana ka Miconazole (me ka hoʻokō ʻana o ka systemic a i ka wā e hoʻohana ai i ka gel ma ka mucosa waha) e hoʻonui i ka hopena hypoglycemic o ka lāʻau (hypoglycemia i ulu a hiki i kahi coma).

Hoʻonui ka Phenylbutazone (hoʻokōnaehana olakino) i ka hopena hypoglycemic o ka lāʻau (hōʻili ʻia ma muli o nā protein plasma a me / a i ʻole a lohi paha i ka ʻōpū mai ke kino), ka pakanikua o ke koko a me ka hoʻoponopono ʻana o ka glyclazide pono, i ka wā o ka mālama phenylbutazone a ma hope o kona haʻalele ʻia.

Hoʻokomo ka Ethanol a me ka ethanol i nā lāʻau me hypoglycemia, ke kāohi nei i nā hopena compensatory, hiki ke kōkua i ka hoʻomohala a me ka hypoglycemic coma.

I ka manawa like me nā lāʻau lapaʻau hypoglycemic ʻē aʻe (insulin, acarbose, biguanides), beta-blockers, fluconazole, ACE inhibitors (captopril, enalapril), histamine H2 receptor blockers (cimetidine), MAO inhibitors, hypoglycemic and sulfanilamides and marked and marked. ka hopena o ka hypoglycemia.

Me ka hoʻohana me ka danazol, ua hōʻike ʻia kahi hopena maʻi maʻa. Pono e kāohi i ka pae o ke kaila o ke koko a hoʻoponopono i ka ʻano o gliclazide, i ka wā o ka mālama o danazol a ma hope o kona haʻalele.

ʻO Chlorpromazine ma nā keke kiʻekiʻe (ʻoi aku ma mua o 100 mg / lā) e hoʻonui i ka ʻike o ka glucose i loko o ke koko, e hoʻemi ana i ka mea huna o ka insulin. Pono e kāohi i ka hoʻoliʻi koko a hoʻoponopono i ka maʻi o gliclazide, i ka wā o ka hoʻokele ʻana o ka chlorpromazine a ma hope o kona haʻalele ʻana.

Hoʻonui ka GCS (systemic, intraarticular, external, rectal administration) i ka hoʻonui ʻana i ka glucose o ke koko me ka hiki ke hoʻomohala ʻana i ka ketoacidosis (hoʻohaʻahaʻa i ka hoʻāʻo ʻana i nā kākūkā). Pono e kāohi i ka hoʻoliʻi koko a hoʻoponopono i ka maʻi o gliclazide ʻelua i ka wā o ka hoʻokele ʻana o GCS a ma hope o kā lākou haʻalele.

ʻO Ritodrine, salbutamol, terbutaline (iv) hoʻonui i ka glucose koko. Hoʻomaopopo ʻia ka mālama koko glucose a, inā pono, ka neʻe ʻana o ka mea maʻi i ka lāʻau maʻi insulin.

Hoʻohui Kūʻai Kūʻai

Ke kūleʻa nei ka lāʻau lapaʻau.

Nā kuleana a me nā kūlana e waiho ai

Papa inoa B. Pono e mālama i ka lāʻau ma kahi maloʻo a maloʻo, i waho o ka hiki o nā keiki i ke ana o ka nui ma mua o 25 ° C. ʻO 3 mau makahiki kahi ola i nā pale.

Hoʻohana no ka hana lawelawe lēwa

Me ka mālama ʻana i ka hiki ʻole o ka ate.

- pilikia hāpau a me / a i ʻole ka palaka kō.

Hoʻohana no ka hana renal impaired

Hoʻohana i nā mea maʻi maʻi

Lawe ʻia ka hana maʻi i loko o ka hui pū ʻana me kahi meaʻai haʻahaʻa haʻahaʻa.

Pono e kiaʻi pinepine i ka pae glucose i loko o ke koko ma luna o ka ʻōpū ʻole a ma hope o ka ʻai ʻana, ʻoi aʻe hoʻi i nā lā mua o ka mālama ʻana me ka lāʻau lapaʻau.

Hiki ke hoʻokaʻawale ʻia ʻo Diabetalong® wale nō i nā mea maʻi e loaʻa mau ana i nā meaʻai maʻamau, ʻo ia ka mea e loaʻa ai ka ʻaina kakahiaka a hāʻawi i ka hoʻopono kūpono o ka paʻakai

Ke kuhikuhi ʻana i ka lāʻau lapaʻau, pono e noʻonoʻo ʻia ma muli o ka komo ʻana o ka derivatives o ka sulfonylurea, hiki i ka hypoglycemia ke ulu, a i kekahi mau pilikia i kahi hana koʻikoʻi a lohi, e koi ana i ka hoʻokipa a me ka hoʻokele glucose i mau lā i kekahi mau lā. Hoʻokomo pinepine ka hypoglycemia me kahi meaʻai haʻahaʻa-haʻahaʻa, ma hope o ka hoʻolōʻihi ʻana a hoʻoikaika ikaika paha, ma hope o ka inu ʻana i ka wai ʻona, a i ʻole lawe ʻana i kekahi mau lāʻau hypoglycemic i ka manawa like.

I mea e pale aku ai i ka hoʻomohala ʻana o ka hypoglycemia, pono ke nānā pono a me ka koho ʻana o kēlā me kēia dosis i ka maʻi, me ka hāʻawi ʻana i ka mea maʻi i ka ʻike holoʻokoʻa e pili ana i ka mālama ʻana i manaʻo ʻia.

Me ka hoʻoulu ʻana o ke kino a me ke kaumaha, i ka wā e hoʻololi nei i ka meaʻai, pono ʻia ka hoʻoponopono ʻana i ka lāʻau Diabetalong®.

Hoʻomaʻamaʻa koʻikoʻi i ka hana o nā lāʻau hypoglycemic he mau kānaka makua, nā mea maʻi e loaʻa ʻole i ka meaʻai kaulike, me kahi kūlana nāwaliwali nui, nā mea maʻi me ka maʻi pituitary-adrenal.

Hiki i nā beta-blockers, clonidine, reserpine, guanethidine ke uhi i nā hōʻike kino o ka hypoglycemia.

Hoʻomaʻamaʻa ʻia nā mea maʻi e pili ana i ka hoʻonui nui o ka hypoglycemia i nā hihia o ka ethanol, NSAID, a me ka pōloli.

I ka hihia o ka ethanol (inu wai), hiki ke hoʻomohala hou i kahi maʻi disulfiram-like (ʻeha o ka ʻōpū, ʻōpū, hoʻohuka, a me ke poʻo).

Hōʻalo ʻia nā ʻoi loa a me nā hōʻeha, a me nā mea ʻē aʻe, nā maʻi ʻeha me ka febrile syndrome e koi ai i ka hoʻopau ʻana i nā lāʻau lapaʻau hypoglycemic waha a me ka koho ʻana i ka maʻi insulin.

Hiki i ka hoʻomohala ʻana o ke kūpaʻa o ka lāʻau lapaʻau kūʻokoʻa (pono e hoʻokaʻawale ʻia mai ka mea maʻamau, kahi e hāʻawi ʻole ʻia ai ka lāʻau lapaʻau i ka hopena lapaʻau i manaʻo ʻia i ka manawa mua).

E kūʻē i ka mea pili i ka lāʻau o ka maʻi Diabetalong®, pono e haʻalele ka mea maʻi i ka hoʻohana ʻana i ka waiʻona a me / a me nā mea e loaʻa ai ka etanol.

I ka wā o ka mālama ʻana me Diabetalong®, pono i ka mea maʻi e hoʻoholo pinepine i nā pae o ka glucose a me ka hemoglobin glycosylated i loko o ke koko, a me ka kikoo glucose i loko o ka urine.

Hoʻokomo i ka hiki ke lawe i nā kaʻa a kāohi i nā mīkini

I ka wā o ka mālama ʻana, pono e mālama ʻia i ka wā e alakaʻi ana i nā kaʻa a hana i nā hana ʻē aʻe paha e koi ai i ka piʻi ʻana o ka nānā a me ka wikiwiki o ka hopena psychomotor.

Diabetalong - nā ʻōlelo pili no ka hoʻohana ʻana

ʻO ka maʻi huakaʻi he mea maʻi ia. Paʻa ʻia ka mea maʻi e lawe i nā lāʻau lapaʻau e hoʻoponopono ai i ke kō koko koko i loko o kona ola.

No ka poʻe maʻi me ka diabetes type 1, ʻo ia ka insulin, a ʻo ke ʻano lua ka lāʻau e pili ana i ka sulfonylurea.

ʻO ka maʻi Diabetalong kahi lāʻau hypoglycemic i kauoha ʻia no nā poʻe me ke koko koko kiʻekiʻe e hōʻemi ai ia mea.

Lawe ʻia ka lāʻau lapaʻau ma ke ʻano, a ma muli o ka hana lōʻihi, hoʻohana ʻia 1, liʻiliʻi pinepine i 2 mau manawa i ka lā.

Hāʻawi ʻia ka lāʻau lapaʻau ʻo ia wale nō he mea hana kūʻokoʻa a i ʻole kahi ʻano hana hui hoʻohui. Hoʻohana ʻia ia i nā hihia kahi e kōkua ʻole ai ka ʻai ʻana, akā lawe ka lāʻau pono pū me nā hoʻoponopono kūpono.

Hōʻike, hoʻokuʻu i ke ʻano

Loaʻa ka maʻi Diabetalong i ke ʻano o nā papa keʻokeʻo poepoe. Hoʻopaʻa ʻia lākou ma nā alapine o 10 mau ʻāpana a me kahi pahu pahu, kahi e hiki ai i nā 3 a 6 mau papa.

Loaʻa ka lāʻau lapaʻau i ʻelua mau huina: 30 mg a me 60 mg o ka mea hana, kahi gliclazide.

Nā mea kōkua o ka lāʻau lapaʻau.

colloidal silicon dioxide,
laktosa lactose,
kaleka kaʻaila
ʻO nā pyromellose
ka leʻaleʻa talcum.

ʻO ke ʻano dosage paha i ke ʻano o nā papa me ka hoʻokuʻu ʻia a i ʻole ka lōʻihi.

Pharmacology a me ka pharmacokinetics

ʻO ka mea hana nui he gliclazide, ma ke ʻano kūlohelohe he mea hohonui ia o ka lua o ka hanauna sulfonylurea. Hōʻike ka Gliclazide i kahi hana koho koho kiʻekiʻe a me ka bioavailability.

He kūpaʻa ia i nā ʻano ʻolaola kūwaho a loaʻa nā hopena penei:

hoʻonui i ka hana o ka insulin proprietary, e ʻae iā ʻoe e hōʻemi i ka nui o ka hormone i paʻi ʻia,
kaoele
hoʻonui i ka hana o nā pehu beta pancreatic,
ho'ēmi i ka platelet fusion, ka mea e pale ai i ka thrombosis a me nā ala ʻē aʻe vascular.

Hoʻopili piha ʻia ka maʻi diabetes ma hope o ka hoʻokele ʻana. Hōʻiliʻili pinepine i loko o ke koko, e hōʻea i kahi kaila nui o nā hola 4-6 ma hope o ka hoʻokele ʻana, e hōʻike ana i kona hopena no nā hola 10-12, a laila e emi loa ka hoʻokaʻawale ʻana o ke ʻano a ma hope o 12 mau hola i hoʻopau ʻia ai ka lāʻau mai ke kino.

Hoʻopili ʻia ka Gliclazide i ka nui o ka ʻā ʻana, a hana ʻia e nā keiki.

Nā hōʻailona a me nā contraindications

ʻO ke kumu no ka lawe ʻana i ka maʻi Diabetalong ka maʻi maʻi o ka mea maʻi - type 2 type diabetes. Hāʻawi ʻia ka lāʻau lapaʻau i hoʻohaʻahaʻa i ka hoʻokahe koko i ka wā i kūpono ʻole ai nā mea i hāʻawi ʻia ʻole.

Eia kekahi, ʻo ka lāʻau lapaʻau ka mea i koho ʻia ma ka prophylactic no nā pilikia i hōʻeha ʻia e ka maʻi mellitus, i hoʻololi nui ʻia i ke ʻano o nā kīʻaha koko ma lalo o ke ʻano o ka glycemia kiʻekiʻe.

Aia nā contraindications no ka lāʻau lapaʻau, ua komo lākou:

maʻi diabetes type 1
lawe ʻia
hōʻeha maʻi nui a me ka renal maikaʻi ʻole,
ka wā hapai a me ka umauma.
ka heleʻana o ka ketoacidosis maʻi, coma a precoma paha,
ka makaʻala loa i nā ʻāpana i hoʻopaʻa i ka lāʻau,
kuʻe o ka lactose metabolism,
makahiki i ka wā ʻelemakule.

ʻO ka mālama a ma lalo o ka mākaʻi o ke kauka, hoʻohana ʻia ka lāʻau lapaʻau:

i loko o ʻelemakule
kanaka ʻai kino ʻole ko lākou ʻai,
nā mea maʻi me nā luʻi cardiovascular,
nā mea maʻi e loaʻa ana mai ka glucose-6-phosphate dehydrogenase nele,
ma hope o ka hoʻomaloka ʻana o ka maʻi glucocorticosteroid,
mea inu wai hoʻohālikelike
ka loaʻa ʻana o ka pūpū a me ka ʻiole ʻole.

I kēia hihia, pono e hoʻoholo ke kauka i ke kumu o ka loaʻa ʻike.

Nā wikiō wikiō mai nā lāʻau lapaʻau:

ʻO nā maʻi maʻi kūikawā

No nā poʻe kahiko ma mua o 65, e koi ʻia kahi hoʻoponopono ʻana. Ma keʻano holoʻokoʻa, hoʻohanaʻia ka lāʻau lapaʻau e like me nā kānāwai like.

I loko o ka wā o ka gestation, ke kauoha ʻia nei ka lāʻau e kahuli ʻia e ka inika insulin a hiki i ka lawe ʻana. ʻAʻoheʻike me ka hoʻohana ʻana o ka maʻi Diabetalong a me nā lāʻau lapaʻau olin glycoside i ka wā hāpai, no laila hiki ʻole ke hoʻoholo i kona hopena ma ka ʻōpio.

I ka wā lactation, ʻaʻole hiki ke hoʻohana ʻia ka lāʻau lapaʻau, no ka mea he hiki ke hoʻomohala i ka hypoglycemia neonatal i loko o ke keiki. No laila, pāpā ʻia ka wahine maʻi maʻi.

ʻO nā mea maʻi me ka hala ʻole ʻana a me nā ala āpau e pono e hoʻopili i nā mea haʻahaʻa, ʻo ka mea nui loa, e kiaʻi mau ʻia e ke kauka hele mai.

Nā ʻōlelo kikoʻī

ʻO kahi kūlana koʻikoʻi no ka lawe ʻana i ka Diabetalong ka meaʻai maʻamau. Pono e kū pono i nā ʻōlelo hōʻike no kēia pūʻulu o nā maʻi a hoʻopaʻa ʻia i ka manawa. Pono kēia e hoʻopau i ka hōʻeha o ka hypoglycemia, hiki i ka mea ma muli o ka nele o kahi kumu wai i ke koko.

ʻO nā kumu i hāʻawi ʻia i ka hiki ʻana o hypoglycemia hiki i nā:

nele i ka nānā ʻana e ka ahonui o kona kūlana ponoʻī,
ka mālama ʻole ʻana i ka hoʻoponopono a nā meaʻai, a me ka pololi, ka pololi, nā meaʻai ʻole i hoʻomākaukau ʻia.
kōpū a āʻe ʻole
ʻOke lāʻau
maʻi maʻi system endocrine,
mismatch o ka pae o ka hana kino a me ka nui o nā karoli i loaʻa,
concurrent hoʻokele o nā lāʻau lapaʻau.

Nā hopena ʻaoʻao a me ka overdose

ʻO nā mea hopena nui ka lawe ʻana i ka lāʻau lapaʻau nā:

lie kanikela
hememia anemia hemolytic,
kuʻe ʻana o ka hoʻāʻo
kūlohelohe, hōʻike pinepine ʻia i ke ʻano o ka ʻāʻī ʻili.

ʻO nā hōʻailona ʻē aʻe paha e kū ʻia:

nahoa
āhāhuʻe
ka hoʻowahāwahā ʻana
ka haʻalulu
ka hana ʻana i ka hanu a me ka hana ʻai ʻana,
hoʻonui hoʻonui ikaika
ho'ēmi i ka maikaʻi o ka hihiʻo
ka maʻi hepatitis o ke ʻano cholestatic.

I kēia hihia, pono e pani i ka lawe ʻana i ka lāʻau lapaʻau a koho i nā ʻatikala e pili ana i nā māhele ʻē aʻe.

Hiki i kahi overdose o ka lāʻau ke kūʻokoʻa inā kūʻokoʻa ʻoe i ka nui o nā lāʻau i lawe ʻia. ʻO kona hopena nui he hypoglycemia, a hiki i kahi coma.

Me ka hypoglycemia i hoʻopaʻa ʻole ʻia, pono e hoʻemi ʻia ka nui o ka nui, a hoʻonui ʻia ka nui o nā hāmeʻe i ka meaʻai. I ka hihia o ka hypoglycemic coma, kahi hoʻonāʻana i kahi hoʻonā intravenous i kuhikuhi ʻia.

Hoʻopili me nā lāʻau lapaʻau ʻē aʻe

Hoʻopau ikaika ʻo Diabetalong me nā mea he nui, no laila ma mua o ka hoʻomaka ʻana o ka lawe ʻana, pono ʻoe e hoʻomaʻamaʻa iā ʻoe iho me kēia ʻano.

No laila, inā ma kahi o ka lawelawe like ʻana:

me ka waiʻona e hiki ai i ka hypoglycemia,
me Danazol, ua hōʻike ʻia kahi hopena maʻi maʻi, e hoʻemi ana i ka hopena o ka lāʻau lapaʻau,
me ka miconazole, ua hoʻonui ʻia ka hopena o ka gliclazide, hiki iā ia ke hāʻawi i ka hoʻopili o ka hypoglycemia, ʻokoʻa ka hopena me nā mea ʻē aʻe hypoglycemic
me ka chlorpromazine, e hoʻemi ana i ka hana o ka insulin, ke hoʻemi nui nei ka hopena o ka lāʻau lapaʻau,
me ka tetracosactide a me glucocorticosteroids hiki ke alakaʻi i ka hoʻomohalaʻana i ka ketoacidosis a me kahi hoʻohaʻahaʻa i ka kāohi kalepa.
me Wafarin a me nā coagulants e hoʻonui i kona hopena.

Hōʻike nā loea o nā kauka he mea maikaʻi loa ka Diabetalong i ka hoʻohaʻahaʻa ʻana i ke kaʻe o ke koko, eia naʻe, ʻaʻole hiki ke hoʻohana mau ʻia.

I kēia hihia, ua kuhikuhi ʻia nā ʻano o nā maʻi Diabetalong, he nui ka nui:

Hoʻomaka ʻia ke Diabetalong a me Diabeton ma ke kumu o ka lako hana like ʻole, akā ʻo ke kīloi hou ke manaʻo ʻia ʻoi aku ka maikaʻi, no ka mea, ʻoi ka hopena o kāna hana he wikiwiki, akā ʻo ke kumukūʻai o kēia lāʻau lapaʻau he 2 mau manawa kiʻekiʻe aʻe. ʻO Glyclazide kahi kikowaena kokoke loa.

Loaʻa ka lōʻihi o ka Glucophage i ka metformin i ka hoʻopili ʻana a hiki ke hoʻohui pū me ka insulin a me nā lāʻau ʻē aʻe e hoʻohaʻahaʻa i ka puna koko.

Nā Manaʻo ʻ Otherlelo ʻē aʻe

ʻO ka hoʻomoʻa ʻana i ka maʻi diabetes

ʻAʻole hiki ke mau i ka mālama ʻana i ke ʻano mellitus type 2 wale nō me ke kōkua o ka meaʻai haʻahaʻa-kākelika a me ka nui o nā muse kino. A he pono e hakakā i ka hyperglycemia, no ka mea, ʻo ka pili maʻi lapaʻau e alakaʻi ai i nā hoʻopiʻi koʻikoʻi.

I waena o nā mea paʻakikī e pili ana i nā pilikia cardiovascular. ʻO ka maʻi Diabetalong (Latin Diabetalong), kahi lāʻau lapaʻau hypoglycemic me kahi hoʻokuʻu lōʻihi a hoʻololi paha, e kōkua i ka hōʻemi o ka hoʻouluʻana i ka CVD.

Hiki i nā pono Pharmacological

ʻO nā waiwai antidiabetic o ka lāʻau lapaʻau ma muli o nā mea hoʻohui gliclazide. Aia i nā papa he 30 a 60 mg o ka mea waiwai a me nā mea hoʻonani: calcium stearate, hypromellose, talc, lactose monxidate, colloidal silicon dioxide.

ʻO ka maʻi Diabetalong kahi lāʻau lapaʻau o ka papa o ka makahiki o ka sulfonylurea.

Ke komo nei ia i ka kahe, me ka hoʻonaninani o ka gliclazide i ka hōʻailona o ka hormone endogenous e nā β-cells o ka pancreas, hoʻihoʻi i ka hoʻohana ʻana i nā glucose (e hoʻolōʻihi ana i ka glycogen synthase).

I loko o kekahi mau lā mai ka hoʻomaka ʻana o ke papa, ʻano maʻamau ka ʻike glycemic. ʻO ka manawa manawa mai ka hoʻokomo ʻana o ka meaʻai i ka digestive tract a hiki i ka hoʻoneʻe ʻana o ka insulin endogenous ua hoʻemi ʻia, a ke hōʻemi nei nā hōʻailona glycemic e ka meaʻai.

He manaʻo ʻino ia i nā makahiki 2 ma hope o ka lawe ʻana i ka lāʻau lapaʻau, mālama ʻia ke ʻano o ka insulin postprandial a me C-peptide. ʻO ka hopena ma ke kino ke Diabetalong he paʻakikī:

Kāohi i ka hoʻoliʻiliʻi o ka hana,
Loaʻa iā ia nā hopena antioxidant hopena,
Hoʻokomo ʻia ka mea huna insulin,
Loaʻa ia he hopena hemovascular (hoʻopaʻa i ka pākuʻi platelet).

Ke komo ka glucose i ke kahe, hiki i ka gliclazide ke hoonui nei i ka hana o ka insulin. Me ka mālama mau ʻana, luhi nei ka lāʻau lapaʻau:

ʻO nā hoʻonā Microvascular - retinopathy (kahi hana hoʻopihapiha ma ka retina) a me ka nephropathy (kahi hana renal)
Nā hopena macrovascular - nā hōʻeha, ka puʻuwai o ka naʻau.

Nā hiʻohiʻona Pharmacokinetic

Mai ka ʻōpū, hoʻohuihue ʻia ka lāʻau i ka piha. Loaʻa ka ʻike kiko loa ma ka kahe koko ma hope o 2-6 mau hola, a no nā papa me MV - 6-12 mau hola.

Hoʻomaʻa ka hopena therapeutic i nā hola 24, a paʻa nā protein glycazide i ka 85-99%. I ka puʻuwai, ua hoʻololi ka huaolaola i nā metabolites, ʻo kekahi o ia mea i ka hopena maikaʻi o ka microcirculation. ʻO ka hapa hapalua he 8-12 mau hola, no nā papa me MB - 12-16 mau hola. Hoʻokuʻu ʻia ka lāʻau lapaʻau e 65% me ka mimi, ma 12% me nā feces.

Nā hopena hopena

Hiki i nā hopena kūpono ʻole no ka hana ʻana i ka huihui e hiki ke make i ka dyspeptic i ke ʻano o ka maʻiila, ka luaʻi ʻana, ka ʻeha o ka ʻōpū. Mai ka ʻaoʻao o ka metabolism, hiki i ka hypoglycemia, no ka ʻōnaehana kao - eosinophilia, cytopenia, anemia. Ma ka ʻāpana o ka ʻili, hiki i nā allergy a me nā photosensitization. Mai nā naʻau sensory aia nā makaʻu hūʻole, nā hōʻeha, ka nalowale o ka hoʻonohonoho ʻana, nalowale o ka ikaika.

Hoʻopili i nā lāʻau lapaʻau

Hoʻonui ʻia ka maikaʻi o ka glycoside me ka hoʻohana pū ʻana me ka anabolic steroid, ACE inhibitors, β-blockers, cimetidine, fluoxetine, salicylates, MAO inhibitors, Flucanazole, Pentoxifylline, Miconazole, Theophylline, Tetracycline.

Hoʻemi ka hiki i ka glyclozide i ka wā i hoʻohana pinepine ʻia me nā barbiturates, glucocorticoids, sympathomimetics, saluretics, rifampicin, nā lāʻau hoʻomalu hānau, estrogens.

Pehea e hoʻopili ai

Pono ke lawe ʻia ʻo Glycloside me ka ʻaina o ka meaʻai. Unuhi ʻia ka papa ʻaʻa, holoi ʻia me ka wai ma ka mahana o ka lumi. Koho ka endocrinologist i nā helu a me ka mālama ʻana i ka mālama ʻana i nā maʻi āpau, e noʻonoʻo ana i ke ʻano o ka maʻi a me ke ʻano o ka maʻi maʻi o ka maʻi maʻi. No ka lāʻau lapaʻau Diabetalong, ʻo nā ʻōlelo aʻo no ka hoʻohana ʻana i ke ʻano o ka hoʻomaka ʻana o 30 mg a me kahi hoʻoponopono hou aʻe ma ke ala o ka hoʻonui (inā pono).

No ka hoʻokō ʻana i ka hopena therapeutic kiʻekiʻe, pono e hahai i nā kānāwai maʻalahi.

Hoʻoikaika ʻia ka hopena holoʻokoʻa o kēlā me kēia lā, ʻoi loa ka maikaʻi - ma ke kakahiaka,
Hiki ke hoʻoponopono ʻia ka nui o ka lāʻau i loko o 30 -120 mg / lā,
Inā poino ʻoe i ka manawa o ke komo ʻana, ʻaʻole hiki iā ʻoe ke pāpālua i ke ʻano o ka lā hiki.
Ke hoʻokaʻawale nei i ka ʻawaʻī, e noʻonoʻo ke kauka i nā heluhelu ʻana o ka glucometer a me HbAlc.

Me ka lawa ʻole o ka hana kūpono, hoʻonui ʻia ke ʻano (ma hope o ke kuʻikahi me ke kauka), akā ʻaʻole ia ma mua o hoʻokahi mahina ma hope o ka hopu mua ʻana o ka glycoside. I kēlā me kēia mau pule 2, me ka uku piha o ka glycemia, hiki ke hoʻonui i ka nui.

He mea pono ke noʻonoʻo i kahi 1 papa o ka Diabetalong PV i loaʻa he 60 mg o ka glyclazide, ua pili kēia me 2 papa o ka Diabetalong MV 30 mg i kēlā

Ke hoʻokaʻa nei i kahi maʻi maʻi i gliclazide mai nā lāʻau lapaʻau hypoglycemic ʻē aʻe, ʻaʻole pono nā hoʻomaha, koe wale nō nā derivatives sulfonylurea. ʻO ka ʻōmua mua ma kēia hihia he maʻamau - 30 mg, inā ʻaʻole i kuhikuhi ka endocrinologist i kāna hana.

I ka hoʻomaʻamaʻa paʻakikī, hoʻohana ʻia ʻo Diabetalong me nā ʻano like ʻole o ka inikini, biagudins, inhibitor α-glucosidase. Me ka mālama aka, ua kuhikuhi ʻia ka lāʻau lapaʻau i ka poʻe maʻi maʻi mai ka hui a me ka hopena hypoglycemic (hōʻino i ka waiʻona, hana hoʻoikaika kino a ʻano haʻukiʻi paha, ka pōloli, ke koʻikoʻi koʻikoʻi). Hoʻopilikia nā hana Hemopoietic me ka hoʻomohala ʻana i ka anemia, thrombocytopenia, leukopenia, granulocytopenia.

ʻO nā mea mālama palekana

I mea e pale ai i ka hypoglycemia, mea koʻikoʻi ka manawa o ka hoʻohana ʻana i nā lāʻau lapaʻau no ka ʻai ʻana, e pale ai i nā wā kaole nui i ka meaʻai, me ka hoʻopau ʻana i ke kao ʻana i ka mea inu meaʻai. ʻO ka hoʻokō ʻana o ka β-blockers hiki ke hoʻokaʻawale i nā hōʻailona o ka hypoglycemia.

Hiki ke hoʻomaopopo i ke kaona hypoglycemic e ke poʻo, ka hui koikoi, hoʻomāhewa ʻole ʻia i ka pōloli, ke kaumaha, nāwaliwali, a me ka pupule blurred, nā maʻi dyspeptic. Hōʻike pū ʻia nā hopena adenergic: hopohopo, ʻeuhe, hoʻokahe i ke kahe o ke koko, maʻi ʻōpio coronary, ʻeha haunaele puʻuwai. ʻO ka maʻi Dyspeptic, ʻo ka haunaele i ka luhi o ka defecation, a me nā hopena kino (rashes, discomfort, erythema, urticaria, Quincke's edema) he ʻano.

ʻAʻole hiki ke hoʻokō maikaʻi ʻia me ka ʻole o kaʻai haʻahaʻa-haʻahaʻa. Ma muli o ka loaʻa ʻana o ka hopena maikaʻi loa, pono e lawe ka poʻe lawe i ka lāʻau lapaʻau me ka mālama. Hoʻololi nā ʻōleka like i nā ʻelele o nā ʻoihana e pili ana i nā helu kiʻekiʻe a me ke neʻe.

Hoʻokomo nā ala ʻehā o nā ate a me nā kēpili i ka hepatitis, he hoʻonui i ka hana enima.

Inā ʻike ka mea ʻai, pono ia e ʻai i nā kīʻaha, inu i ke kīʻaha kīʻaha a i ʻole kekahi mea kiʻekiʻe i nā waihona kālaiʻai. Ma hope o ka holomua o ke ʻano, pono ka endocrinologist e kūkākūkā me ka hoʻoponopono ʻana i ka hopena a i ʻole ke hoʻololi i ka lāʻau lapaʻau.

Nā hiʻohiʻona o ka lāʻau

Wahi a ka māhele ikaika no Diabetalong, ʻo ka analoge ka mea e lilo ai ka Glidiab i hōʻea a hiki i ka 140 rubles. Hāʻawi nā kauka i nā lāʻau Diabeton a me Diabeton MV i kahi kiʻekiʻe kiʻekiʻe i nā kumukūʻai ma waena o 286 a 318 rubles. I nā mākaukau synonymic, hiki ke ʻōlelo pū ʻia ʻo Glyclada.

ʻO ka hoʻomākaukau me ka hopena hypoglycemic like like me Amaril, Glimepiride, Glemaz, Glyurenorm e maikaʻi loa i ka hoʻopili. Ua kuhikuhi ʻia lākou no hypersensitivity a i ʻole nā contraindications no ka glycoside.

Hōʻikeʻike Diabetalong

Ma ka maʻi Diabetolong i loaʻa i nā hopena o ka Diabetolong, ma nā loiloi e hoʻomaopopo i kona pono.

Hoʻololi holomua i nā hōʻailona o ka glucometer,
He kūpono kūpono me nā lāʻau ʻē aʻe,
He kumukūʻai kūpono o nā lāʻau lapaʻau
ʻO ka hiki ke emi ka momona i ka wā mālama.

ʻAʻole mākona nā kānaka āpau i ka pono o ka mālama mau (a hiki i 5 mau manawa i ka lā) ka mana o ka glycemic, akā i ka manawa e kūpaʻa ana kāna mau kuhikuhi a ua emi nā pono no ka mālama pono ʻana.

Ma keʻano holoʻokoʻa, ʻo ka maʻi Diabetalong ke hilinaʻi i ka lāʻau antidiabetic e hoʻopololei maikaʻi i ka kiʻi o ka glycemic. Ke hoʻohana pololei ʻia, hiki iā ia ke pale aku i nā hanana cardiovascular a me nā pilikia koʻikoʻi o ke ʻano maʻi diabetes type 2.